Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18 952) and prognostic value on treatment outcome

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 344-351

  Bouwhuis, Marna G ^a   Collette, Sandra ^e   Suciu, Stefan ^e   De Groot, Els R ^d   Kruit, Wim H ^b   Ten Hagen, Timo L M ^a   Aarden, Lucien A ^d   Eggermont, Alexander M M ^a,f   Swaak, Antonius J G ^c  

^a Division Surgical Oncology   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c IKAZIA HOSPITAL   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

^e EORTC DATA CENTER   (Belgium)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

adjuvant interferon therapy; C reactive protein; ferritin; melanoma; prognostic marker

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; FERRITIN;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; GENDER; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 79960701540     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328346c17f     Document Type: Article

References (33)

1. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203. (Pubitemid 26248989)
2. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99:3505-3516. (Pubitemid 34534516)
3. Hazard JT, Drysdale JW. Ferritinaemia in cancer. Nature 1977; 265: 755-756. (Pubitemid 8039470)
4. Cohen C, Shulman G, Budgeon LR. Immunohistochemical ferritin in testicular seminoma. Cancer 1984; 54:2190-2194. (Pubitemid 15210803)
5. Vaughn CB, Weinstein R, Bond B, Rice R, Vaughn RW, McKendrick A, et al. Ferritin content in human cancerous and noncancerous colonic tissue. Cancer Invest 1987; 5:7-10. (Pubitemid 17112663)
6. Weinstein RE, Bond BH, Silberberg BK. Tissue ferritin concentration in carcinoma of the breast. Cancer 1982; 50:2406-2409. (Pubitemid 13244177)
7. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 2005; 11:3175-3183. (Pubitemid 40627862)
8. Gray CP, Arosio P, Hersey P. Association of increased levels of heavy-chain ferritin with increased CD4 + CD25 + regulatory T-cell levels in patients with melanoma. Clin Cancer Res 2003; 9:2551-2559. (Pubitemid 36842096)
9. Gray CP, Franco AV, Arosio P, Hersey P. Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int J Cancer 2001; 92:843-850. (Pubitemid 32467374)
10. Luger TA, Linkesch W, Knobler R, Kokoschka EM. Serial determination of serum ferritin levels in patients with malignant melanoma. Oncology 1983; 40:263-267. (Pubitemid 13026396)
11. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996; 14:1697-1703. (Pubitemid 26134229)
12. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69: 911-913. (Pubitemid 24140673)
13. Deichmann M, Kahle B, Moser K, Wacker J, Wust K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 2004; 91:699-702. (Pubitemid 39141627)
14. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009; 27:2199-2208.
15. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18 (5 Suppl 7):83-90.
16. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-1677. (Pubitemid 38435557)
17. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29:241-252. (Pubitemid 37069655)
18. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, et al. Interferon alpha as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 2007; 25 (Suppl):8526.
19. Baynes R, Bezwoda W, Bothwell T, Khan Q, Mansoor N. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand J Clin Lab Invest 1986; 46:695-704. (Pubitemid 17171522)
20. Van Iperen CE, Kraaijenhagen RJ, Biesma DH, Beguin Y, Marx JJ, van de Wiel A. Iron metabolism and erythropoiesis after surgery. Br J Surg 1998; 85:41-45. (Pubitemid 28034109)
21. Stam TC, Swaak AJ, Kruit WH, Eggermont AM. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest 2002; 32 (Suppl 1):79-83. (Pubitemid 41704992)
22. Eggermont AM, Suciu S, Mac Kie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18 952): randomised controlled trial. Lancet 2005; 366:1189-1196. (Pubitemid 41393597)
23. Rushton DH, Barth JH. What is the evidence for gender differences in ferritin and haemoglobin? Crit Rev Oncol Hematol 2009; 73:1-9.
24. Wolbink GJ, Bossink AW, Groeneveld AB, de Groot MC, Thijs LG, Hack CE. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis 1998; 177:81-87. (Pubitemid 28030437)
25. Worwood M, Thorpe SJ, Heath A, Flowers CH, Cook JD. Stable lyophilized reagents for the serum ferritin assay. Clin Lab Haematol 1991; 13: 297-305.
26. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17. (Pubitemid 26019991)
27. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-718. (Pubitemid 43247141)
28. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101:869-877.
29. Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, et al. Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 2010; 28:2460-2466.
30. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710-719. (Pubitemid 14202071)
31. Kalbfleisch JD, Prentice RL. The survival analysis of failure time data. 2nd ed. New-Jersey: Wiley Inter-Science; 2002.
32. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007; 13:2422-2428. (Pubitemid 46698593)
33. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117-126. (Pubitemid 351952257)